Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.63 |
| ▸ | FLT3 | P36888 | 5/20 | 0.63 |
| ▸ | KIT | P10721 | 3/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21851723 | 1.00 | CSF1R (0.64) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824022 | 0.95 | CSF1R (0.64) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824035 | 0.87 | CSF1R (0.66) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824034 | 0.86 | CSF1R (0.69) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824020 | 0.85 | CSF1R (0.68) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824000 | 0.83 | CSF1R (0.65) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21823997 | 0.83 | CSF1R (0.72) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL16046106 | 0.82 | CSF1R (0.73) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824032 | 0.82 | CSF1R (0.64) | CSF1RPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL21824006 | 0.82 | CSF1R (0.65) | CSF1RPDGFRBPDGFRAFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632906-B1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-3632906-B1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3632906-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632906-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | FAR1, CSF1R, CSF3R | CSF1R 2/4885PDGFRB 891/4885PDGFRA 977/4885 |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | FAR1, CSF1R, CSF3R | CSF1R 2/4885PDGFRB 891/4885PDGFRA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.